Close
FINDING CURES TOGETHER<sup>SM</sup>

CIMM Election Results

Congratulations to Kunle Odunsi, MD, PhD, CIMM Chairperson-elect 2020-2021

Our thanks to Kunle Odunsi, MD, PhD, and Eduardo M. Sotomayor, MD, for standing for election and to the membership of CIMM for participating in the election. Congratulations to Dr. Odunsi for having been elected as CIMM chairperson-elect. Dr. Odunsi will assume the office of chairperson-elect at the AACR Annual Meeting 2020, April 24-29, in San Diego, California.

Kunle OdunsiKunle Odunsi, MD, PhD
Cancer Center Deputy Director
The M. Steven Piver Professor and Chair, Department of Gynecologic Oncology
Executive Director, Center for Immunotherapy
Roswell Park Cancer Institute
Buffalo New York

Other Positions Currently Held
Co-chair, Ovarian Task Force of the NCI Gynecologic Cancer Steering Committee,2013-2019
Co-chair, NCI Cancer Moonshot Immuno-oncology Translational Network (IOTN) Steering Committee, 2018–2023
Member, NCI Transplantation, Tolerance, and Tumor Immunology (TTT) Study Section, 2017-2021
Member, NCI Cancer Center Subcommittee-A Initial Review Group, 2017-2021
Co-chair, Scientific Program Committee, AACR Annual Meeting 2019
ASCO Representative, ASCO-SITC Clinical Immuno-Oncology Symposium, 2017-2020
Editorial Board Member: Cancer Immunology Research (an AACR Journal); Oncoimmunology; JITC.
Member, National Academy of Medicine, elected 2018
Member, AACR-Cancer Immunology Working Group (CIMM) Steering Committee, 2018-2021

Education
1984: MD, University of Ife, Ile-Ife, Nigeria
1991: MRCOG, Royal College of Obstetricians and Gynecologists, United Kingdom
1995: PhD, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Research Interests/Vision Statement
I am a translational research physician-scientist with long-standing expertise in tumor immunology and immunotherapy. My research has focused on the mechanisms of immune recognition and tolerance in human ovarian cancer, and the translation of the findings to clinical immunotherapy trials. This led to several first-in-human clinical trials to elicit antigen-specific responses in ovarian cancer patients. Recently, my group has focused on pre-clinical and clinical development of “next generation” adoptive T cell immunotherapies for solid tumors. I am the overall PI of an NCI-funded Specialized Program of Research Excellence (SPORE) in Ovarian Cancer completely focused on overcoming mechanisms of immune escape. I am the author or co-author of over 350 peer-reviewed journal articles, and serve on the editorial board of several journals.

As chairperson-elect, I will help CIMM serve our community as an inclusive working group; enable teamwork required to make the next advances in cancer immunology research; and bring people together in new alliances to pursue strategic objectives and creative new directions. I will ensure that our collective mission to develop the best science is applied most effectively, and promote efforts to train and mentor the next generation of investigators. I will make CIMM a major voice in AACR for communicating and advocating for cancer immunology research and the need for resources to further propel the immunology revolution to its ultimate destination of changing cancer from a terrifying disease to that of a potentially curable disease.